LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

SNIBE Displays Super High Throughput CLIA Analyzer Powered by X Tech Technology

By LabMedica International staff writers
Posted on 21 May 2023
Print article
Image: The MAGLUMI X series CLIA analyzers is powered by X Tech technology (Photo courtesy of Snibe)
Image: The MAGLUMI X series CLIA analyzers is powered by X Tech technology (Photo courtesy of Snibe)

Snibe (Shenzhen, China) is showcasing its latest products with high-performance features at Euromedlab Roma 2023, including the newest member of its X-series of new-generation chemiluminescence immunoassay (CLIA) analyzers.

MAGLUMI X Tech is the core technology powering the X series of fully automatic CLIA analyzers which provide more efficient, convenient, and reliable immunology diagnostic solutions for laboratories and hospitals. The technology helps the X series analyzers deliver an amazing performance, higher accuracy, and further precision, while also making them affordable and easy to operate. The MAGLUMI X series offers three models to meet all types of demands. The small but smart MAGLUMI X3 is a small-footprint desktop analyzer having a throughput of 200 t/h, 20 reagent positions, and 72 sample positions to target for small- and mid-size laboratories and hospitals.

The most cost-effective analyzer and the newest member of the X-series - MAGLUMI X6 - with a higher throughput of up to 450 T/h offers up to 30 reagent positions and up to 112 sample positions, or up to 412 when integrated with a sample-storage module. The fastest analyzer in the X series - MAGLUMI X8 - is the most powerful CLIA analyzer that offers a super-high throughput of 600 t/h while ensuring the highest level of precision. It offers 42 reagent positions and 300 sample positions. MAGLUMI X8 can be integrated with the Biossays C8 to create the Biolumi CX8 biochemical and immunological integrated analyzer.

Aided by the incredible X Tech, the MAGLUMI X series CLIA analyzers possess even more powerful capabilities such as patented pipetting technology, accurate incubation technology, stable and precise measuring technology, multiple expansion solutions, and user-friendly and high-efficiency loading design. These latest high-end features help the MAGLUMI X series CLIA analyzers to provide better immunology diagnostic capabilities for laboratories and hospitals.

Related Links:
Snibe 

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Signs of multiple sclerosis show up in blood years before symptoms appear (Photo courtesy of vitstudio/Shutterstock)

Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset

Autoimmune diseases such as multiple sclerosis (MS) are thought to occur partly due to unusual immune responses to common infections. Early MS symptoms, including dizziness, spasms, and fatigue, often... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more